Offering Details: VolitionRx Limited (NYSE AMERICAN: VNRX) priced a public offering of 2,960,000 shares of common stock and warrants to purchase up to 1,480,000 additional shares at a combined price of $1.55 per share. The company expects gross proceeds of approximately $4.6 million before placement agent fees and other offering expenses. The transaction is expected to close on 9 June 2026, subject to customary closing conditions.
Warrant Terms: Each warrant has an exercise price of $1.55 per share, becomes exercisable immediately upon issuance, and expires five years after the issuance date. If all warrants are exercised on a cash basis, the company would receive an additional $2.3 million in gross proceeds.
Market Context: The stock trades at $1.79, just above its 52‑week low of $1.75, giving the company a market capitalization of about $14.18 million. Maxim Group LLC acted as the sole placement agent.
Regulatory Filing: The securities are offered pursuant to an effective shelf registration statement on Form S‑3 (File No. 333‑283088), initially filed with the SEC on 8 Nov 2024 and declared effective on 18 Apr 2025.
Business Overview: VolitionRx develops blood tests for disease detection and monitoring, with R&D activities centered in Belgium and facilities in the United States and London.
Quarterly Performance (Q1 2026): Revenue reached $1 million, a 300 % increase year‑over‑year. Earnings per share were –$0.97, versus a forecast of –$0.04, representing a –2,325 % surprise. The company ended the quarter with $3.1 million in cash.
Milestone Payment: The company is nearing a $5 million milestone payment contingent on the anticipated publication of a clinical manuscript for its Nu.Q Vet cancer test in cats.
Governance Update: Director Mickie Henshall, who has served since August 2022, will not stand for re‑election at the 2026 Annual Meeting of Stockholders.
Covenant Waiver: VolitionRx secured a waiver and consent agreement with Lind Global Asset Management XII LLC after failing to meet a market‑capitalization covenant tied to its convertible promissory notes.
Analyst Commentary: Benchmark reiterated a Hold rating, noting the company’s plans to further reduce cash burn in 2026.
